secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K
Filed at:   2023-08-07T23:59:59+00:00
Accession:  0001104659-23-088346
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theravance Biopharma Q2 2023: YUPELRI sales up 12% YoY; $80.5M in share buybacks
--------------------------------------------------------------------------------

- YUPELRI net sales recognized by Viatris: $55.0M, up 12% YoY; Theravance's 35% share implies $19.3M.
- YUPELRI retail TRx and new-to-product TRx hit all-time highs, up 26% and 53% YoY (Symphony Health).
- PIFR-2 enrollment nearing completion; top-line data late Q4 2023, disclosure expected Jan 2024.
- $80.5M share repurchases in Q2 2023 ($263.8M cumulative); $61.2M remaining in $325M program to complete by year-end.
- TRELEGY ELLIPTA Q2 global net sales $760M (+29% YoY); $50M milestone from Royalty Pharma if 2023 sales ≥ $2.9B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465923088346/0001104659-23-088346-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465923088346/tm2322953d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-088346

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer